Ocular Therapeutix (OCUL) Competitors $12.70 -0.24 (-1.85%) Closing price 04:00 PM EasternExtended Trading$12.80 +0.10 (+0.79%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OCUL vs. ROIV, RVMD, GRFS, RYTM, LEGN, ABVX, AXSM, RNA, NUVL, and MRUSShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), Nuvalent (NUVL), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. Its Competitors Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Axsome Therapeutics Avidity Biosciences Nuvalent Merus Ocular Therapeutix (NASDAQ:OCUL) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Do institutionals & insiders hold more shares of OCUL or ROIV? 59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 2.3% of Ocular Therapeutix shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to OCUL or ROIV? In the previous week, Roivant Sciences had 14 more articles in the media than Ocular Therapeutix. MarketBeat recorded 18 mentions for Roivant Sciences and 4 mentions for Ocular Therapeutix. Roivant Sciences' average media sentiment score of 1.35 beat Ocular Therapeutix's score of 0.31 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 9 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer OCUL or ROIV? Ocular Therapeutix currently has a consensus price target of $17.20, suggesting a potential upside of 35.43%. Roivant Sciences has a consensus price target of $16.38, suggesting a potential upside of 30.27%. Given Ocular Therapeutix's higher probable upside, research analysts plainly believe Ocular Therapeutix is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20 Is OCUL or ROIV more profitable? Ocular Therapeutix has a net margin of -382.51% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-382.51% -71.92% -49.36% Roivant Sciences -2,111.79%-15.90%-14.95% Which has more risk & volatility, OCUL or ROIV? Ocular Therapeutix has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Which has higher earnings & valuation, OCUL or ROIV? Roivant Sciences has lower revenue, but higher earnings than Ocular Therapeutix. Roivant Sciences is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$63.72M34.68-$193.51M-$1.28-9.92Roivant Sciences$29.05M295.48-$171.98M-$0.70-17.96 SummaryRoivant Sciences beats Ocular Therapeutix on 11 of the 17 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.21B$2.54B$5.76B$9.91BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-9.9222.7183.0126.65Price / Sales34.68538.47503.03163.66Price / CashN/A26.3325.7028.92Price / Book7.226.7910.796.52Net Income-$193.51M$32.94M$3.29B$266.21M7 Day Performance1.44%0.48%0.02%-0.76%1 Month Performance2.83%6.61%7.06%3.83%1 Year Performance50.65%-0.50%50.09%24.39% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.4334 of 5 stars$12.70-1.9%$17.20+35.4%+55.0%$2.21B$63.72M-9.92230ROIVRoivant Sciences3.1663 of 5 stars$11.93-0.1%$16.50+38.3%+7.0%$8.15B$29.05M-17.04860News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.4891 of 5 stars$37.97-0.9%$69.92+84.2%-4.3%$7.10B$11.58M-8.44250Positive NewsGRFSGrifols3.9231 of 5 stars$9.97+1.0%$10.30+3.3%+2.2%$6.85B$7.81B8.5223,822Positive NewsGap UpRYTMRhythm Pharmaceuticals3.3217 of 5 stars$103.15-1.0%$101.57-1.5%+121.3%$6.85B$130.13M-34.27140News CoveragePositive NewsLEGNLegend Biotech3.527 of 5 stars$34.73+1.0%$74.22+113.7%-37.3%$6.41B$627.24M-39.472,609ABVXAbivax2.4558 of 5 stars$81.03-0.7%$92.33+13.9%+574.1%$6.12BN/A0.0061News CoveragePositive NewsShort Interest ↓AXSMAxsome Therapeutics4.7788 of 5 stars$121.28-0.4%$178.00+46.8%+36.1%$6.05B$385.69M-23.92380News CoveragePositive NewsAnalyst ForecastInsider TradeRNAAvidity Biosciences3.2021 of 5 stars$46.58-4.1%$67.00+43.8%+16.1%$5.99B$10.90M-13.08190Positive NewsNUVLNuvalent3.2446 of 5 stars$76.58+0.7%$120.80+57.7%-4.9%$5.52BN/A-15.6340News CoveragePositive NewsAnalyst ForecastMRUSMerus3.0251 of 5 stars$65.84-0.4%$88.75+34.8%+32.0%$4.98B$36.13M-11.9737News CoveragePositive News Related Companies and Tools Related Companies ROIV Competitors RVMD Competitors GRFS Competitors RYTM Competitors LEGN Competitors ABVX Competitors AXSM Competitors RNA Competitors NUVL Competitors MRUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCUL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
